Emraclidine 30 mg
Sponsors
AbbVie
Conditions
Schizophrenia
Phase 2
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
CompletedNCT05227703
Start: 2022-07-05End: 2024-09-11Updated: 2025-10-28
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
CompletedNCT05227690
Start: 2022-06-30End: 2024-08-26Updated: 2025-09-17
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
TerminatedNCT05443724
Start: 2022-09-01End: 2025-06-25Updated: 2026-08-21